Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:FLUT
NYSE:FLUTHospitality

A Look At Flutter Entertainment’s (NYSE:FLUT) Valuation As Buybacks Continue And Analyst Outlook Turns Cautious

What is moving Flutter Entertainment stock right now? Flutter Entertainment (NYSE:FLUT) is in focus after a combination of events, including an ongoing multi billion dollar buyback, a reduced analyst outlook for U.S. online gaming, and a large stake build by investor Kenneth Dart. See our latest analysis for Flutter Entertainment. At a share price of $105.25, Flutter’s recent 1 day and 90 day share price returns of 3.89% decline and 51.11% decline sit alongside a 1 year total shareholder...
NasdaqGS:POWI
NasdaqGS:POWISemiconductor

Is Power Integrations (POWI) Fairly Valued After Recent Share Price Momentum And Growth Expectations

Power Integrations (POWI) has been drawing attention after recent share price moves, with the stock last closing at US$54.54. Investors are weighing this against its reported US$443.504 million revenue and US$22.093 million net income. See our latest analysis for Power Integrations. The recent 21.01% 1 month share price return and 31.39% 3 month share price return suggest momentum has picked up. However, the 3 year total shareholder return of 29.24% and 5 year total shareholder return of...
TSE:7261
TSE:7261Auto

What Mazda Motor (TSE:7261)'s Middle East Export Pause and Safety Push Mean For Shareholders

Mazda Motor recently halted vehicle exports to the Middle East until May after the Strait of Hormuz was shut, redirecting factory capacity toward US and European markets to keep overall production volumes steady. At the same time, a Mazda North American survey highlighted how drivers increasingly prioritize safety, comfort, and human-centric technology over traditional luxury badges, aligning with Mazda’s recent recognition as Consumer Reports’ first-ever Safest New-Car Brand. Next, we...
NYSE:AHR
NYSE:AHRHealth Care REITs

Will Extended Credit Maturities and ATM Program Redefine American Healthcare REIT's (AHR) Funding Flexibility?

American Healthcare REIT, Inc. has already amended its primary credit facility and launched a US$1.75 billion at-the-market equity program, extending revolving loan maturities to April 1, 2030 and increasing borrowing flexibility under tighter leverage and coverage covenants. This combination of longer-dated debt capacity and flexible equity issuance reshapes the REIT’s funding toolkit, potentially affecting how it balances growth, balance sheet strength and future portfolio decisions. Next,...
NasdaqGS:LPLA
NasdaqGS:LPLACapital Markets

Does LPL Financial (LPLA) Insurance Push With Simplicity Quietly Redefine Its Platform Advantage?

In early April 2026, UBS upgraded LPL Financial Holdings to Buy, arguing that earlier AI-related concerns were overdone and highlighting the firm’s new partnership with Simplicity Group to broaden insurance solutions for more than 32,000 affiliated advisors overseeing about US$2.40 trillion in client assets. The Simplicity Group agreement, which makes Simplicity LPL’s preferred Brokerage General Agency from May 2026, could deepen LPL’s insurance capabilities and reinforce its position as a...
NYSE:EIX
NYSE:EIXElectric Utilities

Surge in Call Options and STEM Scholarships Could Be A Game Changer For Edison International (EIX)

In early April 2026, investors traded a very large volume of call options on Edison International and several analysts updated their views on the company, while Edison also awarded US$50,000 Edison Scholars scholarships to 30 high school seniors pursuing STEM degrees, funded entirely by its shareholders. Together, the surge in options activity and fresh analyst commentary highlight shifting market expectations for Edison International at the same time the company is emphasizing...
NasdaqCM:VRDN
NasdaqCM:VRDNBiotechs

Viridian Therapeutics (VRDN) Is Down 18.4% After Strong REVEAL-1 Elegrobart TED Data - What's Changed

Viridian Therapeutics recently reported positive topline data from its Phase 3 REVEAL-1 trial of elegrobart in active thyroid eye disease, showing statistically significant improvements in eye bulging and double vision with subcutaneous dosing every four or eight weeks versus placebo. Beyond meeting key efficacy endpoints, elegrobart’s low rate of mostly mild, tinnitus-only hearing effects may distinguish it within the anti‑IGF‑1R class as Viridian advances toward a planned Biologics...
NasdaqGS:NDSN
NasdaqGS:NDSNMachinery

A Look At Nordson (NDSN) Valuation After Q1 2026 Results Dividend And Board Changes

Q1 earnings, dividend and board changes set the stage for Nordson (NDSN) Nordson (NDSN) drew fresh investor attention after first quarter fiscal 2026 results met earnings expectations while revenue came in ahead of forecasts, alongside a US$0.82 dividend declaration and new board appointments. See our latest analysis for Nordson. The recent first quarter update appears to be the key driver behind Nordson’s 5.8% 90 day share price return and 54.7% one year total shareholder return, with the...
ENXTPA:RI
ENXTPA:RIBeverage

Reassessing Pernod Ricard (ENXTPA:RI) Valuation After Recent Share Price Rebound And Perceived 31% Discount

Why Pernod Ricard Is Back On Investors’ Radar Pernod Ricard (ENXTPA:RI) is drawing renewed attention after a period of weak share price performance, with the stock showing a return of about 9% over the past day and 3% over the past week. That rebound comes after declines of roughly 9% over the past month and 13% over the past 3 months, alongside a 24% total return decline over the past year. This performance may prompt investors to reassess the current valuation. See our latest analysis for...
NasdaqGS:COLL
NasdaqGS:COLLPharmaceuticals

Assessing Collegium Pharmaceutical (COLL) Valuation After Mixed Recent Share Price Performance

Why Collegium Pharmaceutical is on investors' radar Collegium Pharmaceutical (COLL) has attracted attention after a period of mixed share performance, including a 4.4% gain over the past week alongside a negative move over the past 3 months and year to date. See our latest analysis for Collegium Pharmaceutical. Despite a 42.89% 1 year total shareholder return, the recent 22.6% 3 month share price decline and softer 30 day share price return suggest momentum has cooled after a strong run. If...
SEHK:2533
SEHK:2533Semiconductor

Assessing Black Sesame International Holding’s Valuation After Its Swing To A Full Year Net Loss

What the latest earnings mean for Black Sesame International Holding (SEHK:2533) Black Sesame International Holding (SEHK:2533) recently reported full year 2025 earnings, with sales of CNY 822.33 million and a net loss of CNY 1,424.7 million compared with net income a year earlier. This sharp swing into loss is a key reference point for how investors may be thinking about the stock today, especially given the company’s role in automotive grade autonomous driving chips and related...
NYSE:VNO
NYSE:VNOOffice REITs

Does Vornado (VNO) Use Sustainability Leadership To Redefine Its Capital Allocation Priorities?

Vornado Realty Trust recently released its 2025 Sustainability Report and furnished its latest Annual Report and Chairman’s Letter, highlighting 100% LEED and WELL Health-Safety certifications across its portfolio and recognition for THE PENN DISTRICT as New York City’s Redevelopment of the Year. Together, these disclosures give investors a fresh window into Vornado’s progress on large redevelopment projects, sustainability priorities, and management’s current expectations for capital...
NYSE:JLL
NYSE:JLLReal Estate

Assessing Jones Lang LaSalle (JLL) Valuation As Shares Sit Below Estimated Fair Value

Jones Lang LaSalle (JLL) at a glance Jones Lang LaSalle (JLL) has drawn fresh attention after recent trading left the shares at $320, with mixed return patterns over the past month and past 3 months prompting closer scrutiny from real estate focused investors. See our latest analysis for Jones Lang LaSalle. The recent 8.27% 1 month share price return contrasts with an 8.58% 3 month share price decline, while the 1 year total shareholder return of 50.02% points to momentum that has built up...
OM:EPI A
OM:EPI AMachinery

Assessing Epiroc (OM:EPI A) Valuation After New Underground Mining Charging Solutions Launch

What Epiroc’s new charging launch means for the stock Epiroc (OM:EPI A) has introduced a new generation of charging solutions for underground mining and heavy duty electrification, designed for tough conditions and OEM agnostic use, with global availability starting in April 2026. This launch puts a spotlight on how the business is positioning its equipment and service offering around electrified mines, at the same time that investors reassess the long term prospects of the wider mining...
NYSE:L
NYSE:LInsurance

Is CNA’s Richer Dividend Strategy Reframing Loews’ (L) Income Story Amid Financial Sector Jitters?

Earlier this week, Loews drew attention after its key subsidiary CNA Financial announced a 4% increase to its regular dividend and a special dividend on April 7, 2026, highlighting strong cash generation and management confidence at the insurance unit. The subsequent reassessment of this dividend news against a backdrop of choppy sentiment toward financial stocks has turned CNA’s payout decision into a broader gauge of how investors are weighing income potential against sector-wide...
NYSE:BROS
NYSE:BROSHospitality

Dutch Bros (BROS) Is Up 10.9% After Analyst Upgrades And Expansion Push Has The Bull Case Changed?

In recent days, Dutch Bros has drawn fresh attention as multiple research firms initiated or upgraded coverage while the company continued rolling out new drive-thru locations across high-growth U.S. markets. This combination of favorable analyst commentary and evidence of disciplined expansion, underpinned by a highly penetrated loyalty program, has sharpened investor focus on the brand’s scalability and customer engagement. Now we’ll explore how this reinforced focus on disciplined unit...
NYSE:OSCR
NYSE:OSCRInsurance

Oscar Health (OSCR) Is Up 22.0% After CEO’s $11.9M Buy And Medicare Tailwind News – Has The Bull Case Changed?

In early April 2026, Oscar Health drew attention after CEO Mark Bertolini bought 1,000,000 shares for US$11.92 million and regulators finalized 2027 Medicare Advantage reimbursement increases that will add more than US$13.00 billion in payments across the industry. The combination of a rare insider purchase amid prior insider selling and policy-driven revenue tailwinds for managed-care players is prompting investors to reassess Oscar Health’s longer-term positioning and risk-reward...
NasdaqGS:PEBO
NasdaqGS:PEBOBanks

Assessing Peoples Bancorp (PEBO) Valuation After Dividend Strength And Banking Sector Stabilization

Peoples Bancorp (PEBO) has drawn fresh attention after its share price moved above its long term average. This coincides with steadier banking sector conditions and renewed focus on the stock’s dividend and earnings outlook. See our latest analysis for Peoples Bancorp. The latest move above its long term average comes on top of a 9.19% 1 month share price return and a 12.49% 3 month share price return. The 1 year total shareholder return of 35.73% and 3 year total shareholder return of 60.23%...
NasdaqGS:BIDU
NasdaqGS:BIDUInteractive Media and Services

Assessing Baidu (BIDU) Valuation After Apollo Go’s Fully Driverless Launch In Dubai

Dubai launch puts Apollo Go in global focus Baidu (BIDU) is in the spotlight after Apollo Go launched a fully driverless commercial ride hailing service in Dubai, its first international app deployment and a key test of investor appetite for the stock. See our latest analysis for Baidu. Despite the Dubai launch drawing fresh attention to Apollo Go, Baidu’s share price has had a weaker patch, with a 1-month share price return of 13.76% and a year to date share price return of 27.99%. The...
NasdaqGS:AMLX
NasdaqGS:AMLXPharmaceuticals

Amylyx Pharmaceuticals (AMLX) Is Up 15.9% After FDA ALS Drug Approval Boosts Analyst Optimism – Has The Bull Case Changed?

Amylyx Pharmaceuticals recently saw increased analyst attention after the FDA approved its lead therapy AMX0035 for amyotrophic lateral sclerosis, reinforcing its focus on rare neurological diseases. This wave of analyst optimism underscores how regulatory progress on AMX0035 may influence expectations for Amylyx’s broader pipeline and long-term business potential. We’ll now explore how this renewed analyst confidence following AMX0035’s FDA approval could influence Amylyx Pharmaceuticals’...
NYSE:DNOW
NYSE:DNOWTrade Distributors

A Look At DNOW (DNOW) Valuation After ERP Disruption And Securities Fraud Investigation

ERP issues and legal investigation put DNOW (DNOW) under closer scrutiny DNOW (DNOW) is in focus after the Portnoy Law Firm began probing potential securities fraud, following the company’s disclosure that a new Enterprise Resource Planning system created operational issues and financial impacts. See our latest analysis for DNOW. At a share price of US$12.25, DNOW has seen a 5.33% 30 day share price return but a 9.73% 90 day share price decline. The 1 year total shareholder return of 18.82%...
NYSE:WRBY
NYSE:WRBYSpecialty Retail

Coastal Financial And 2 Other Growth Companies With Strong Insider Confidence

The United States market has shown robust performance, climbing 3.4% in the last 7 days and rising 30% over the past year, with earnings projected to grow by 16% annually in the coming years. In such an environment, growth companies with high insider ownership often attract attention as they may signal strong confidence from those closest to the business's operations and future prospects.
NasdaqGS:CSTE
NasdaqGS:CSTEBuilding

April 2026 Penny Stocks With Promising Potential

The market has climbed 3.4% in the last 7 days and an impressive 30% over the past year, with earnings projected to grow annually by 16%. In light of these robust market conditions, identifying stocks with strong financials becomes crucial for investors looking to capitalize on growth opportunities. Although often considered a relic, penny stocks still hold potential when backed by solid fundamentals, offering a unique blend of value and growth that might not be found in larger companies.